Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

W. Kielbasa · SciRah

Researcher profile · Semantic Scholar

W. Kielbasa

Share profile

W. Kielbasa — researcher profile on SciRah

h-index: 15
Works: 39
Citations: 750

Most-cited papers

Neurokinin 1 Receptor Antagonism as a Possible Therapy for Alcoholism
D. T. George, J. Gilman, Jacqueline Hersh, A. Thorsell +11 more
2008Science107 citations
Semantic Scholar
Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S,S)-[18F]FMeNER-D2
N. Seneca, B. Gulyás, A. Varrone, M. Schou +7 more
2006Psychopharmacology81 citations
Semantic Scholar
A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody
W. Kielbasa, D. Helton
2019Cephalalgia68 citations Open access
Semantic Scholar
Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder.
J. Tauscher, W. Kielbasa, S. Iyengar, F. Vandenhende +4 more
2010European Neuropsychopharmacology53 citations
Semantic Scholar
Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study
T. Oakes, V. Skljarevski, Qi Zhang, W. Kielbasa +4 more
2018Cephalalgia47 citations
Semantic Scholar
Microdialysis Evaluation of Atomoxetine Brain Penetration and Central Nervous System Pharmacokinetics in Rats
W. Kielbasa, J. C. Kalvass, R. Stratford
2009Drug Metabolism And Disposition42 citations
Semantic Scholar
Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies
V. Stauffer, Ryan Sides, M. Lanteri-Minet, W. Kielbasa +3 more
2018Patient Preference and Adherence39 citations Open access
Semantic Scholar
Discovery and clinical translation of ceperognastat, an O‐GlcNAcase (OGA) inhibitor, for the treatment of Alzheimer's disease
W. Kielbasa, Pauline Goldsmith, K. Donnelly, H. Nuthall +18 more
2024Alzheimer's & Dementia36 citations Open access
Semantic Scholar
A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression.
S. Dubé, M. Dellva, Marcia Jones, W. Kielbasa +3 more
2010Journal of Psychiatric Research33 citations
Semantic Scholar
Population Pharmacokinetics of Galcanezumab, an Anti‐CGRP Antibody, Following Subcutaneous Dosing to Healthy Individuals and Patients With Migraine
W. Kielbasa, Tonya Quinlan
2019Journal of clinical pharmacology32 citations Open access
Semantic Scholar
Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor‐Positive Allosteric Modulator (D1PAM), in Healthy Subjects
D. Wilbraham, K. Biglan, Kjell A. Svensson, Max C. Tsai +1 more
2020Clinical pharmacology in drug development22 citations Open access
Semantic Scholar
Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme: Translation from rat to human
S. Shcherbinin, W. Kielbasa, Susan Dubois, S. L. Lowe +18 more
2020Alzheimer's & Dementia21 citations Open access
Semantic Scholar
A Randomized Trial of Edivoxetine in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder
D. Lin, C. Kratochvil, Wen Xu, Ling Jin +3 more
2014Journal of child and adolescent psychopharmacology20 citations Open access
Semantic Scholar
Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials
V. Stauffer, Ira M. Turner, P. Kemmer, W. Kielbasa +4 more
2020The Journal of Headache and Pain16 citations Open access
Semantic Scholar
Pharmacokinetics and pharmacodynamics of edivoxetine (LY2216684), a norepinephrine reuptake inhibitor, in pediatric patients with attention-deficit/hyperactivity disorder.
W. Kielbasa, Tonya Quinlan, Ling Jin, Wen Xu +3 more
2012Journal of child and adolescent psychopharmacology16 citations
Semantic Scholar
Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine
James Martinez, Nada Hindiyeh, G. Anglin, K. Kalidas +5 more
2020Cephalalgia13 citations Open access
Semantic Scholar
A pharmacokinetic/pharmacodynamic investigation: assessment of edivoxetine and atomoxetine on systemic and central 3,4-dihydroxyphenylglycol, a biochemical marker for norepinephrine transporter inhibition.
W. Kielbasa, Alan X Pan, Álvaro Pereira
2015European Neuropsychopharmacology12 citations
Semantic Scholar
A single ascending dose study in healthy volunteers to assess the safety and PK of LY3372689, an inhibitor of O‐GlcNAcase (OGA) enzyme
W. Kielbasa, K. Phipps, J. Tseng, F. Natanegara +15 more
202011 citations Open access
Semantic Scholar
Clinical Outcomes from an Open-Label Study of Edivoxetine Use in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder
Ling Jin, Wen Xu, D. Krefetz, D. Gruener +3 more
2013Journal of child and adolescent psychopharmacology11 citations
Semantic Scholar
Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme, following administration of single and multiple doses to healthy volunteers
W. Kielbasa, S. Shcherbinin, Paul Goldsmith, K. Phipps +9 more
2021Alzheimer's & Dementia9 citations
Semantic Scholar
The Dopamine D1 Receptor Positive Allosteric Modulator Mevidalen (LY3154207) Enhances Wakefulness in the Humanized D1 Mouse and in Sleep-Deprived Healthy Male Volunteers
Andrew P McCarthy, Kjell A. Svensson, E. Shanks, C. Brittain +4 more
2021Journal of Pharmacology and Experimental Therapeutics7 citations Open access
Semantic Scholar
Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor–Positive Allosteric Modulator, in Patients With Parkinson Disease
D. Wilbraham, K. Biglan, Kjell A. Svensson, Max C. Tsai +3 more
2021Clinical pharmacology in drug development7 citations Open access
Semantic Scholar
Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4‐dihydroxyphenylglycol in humans
W. Kielbasa, E. Lobo
2015Journal of clinical pharmacology7 citations
Semantic Scholar
Relationship between steady-state pharmacokinetics and hemodynamic effects of inhaled isobutyl nitrite in conscious rats
W. Kielbasa, H. Fung
2000AAPS PharmSci7 citations Open access
Semantic Scholar
Single and multiple ascending dose studies in healthy volunteers to assess the safety and PK of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme
S. L. Lowe, Paul Goldsmith, K. Phipps, Donnelly B. Kevin +5 more
2021Alzheimer's & Dementia6 citations Open access
Semantic Scholar
Ceperognastat in Early Symptomatic Alzheimer Disease: A Randomized Clinical Trial.
A. S. Fleisher, L. Munsie, M. Mancini, Yun‐Ju Cheng +10 more
2026Journal of the American Medical Association (JAMA)5 citations Open access
Semantic Scholar
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Galcanezumab, a Monoclonal Antibody to Calcitonin Gene-Related Peptide, in Healthy Japanese and Caucasian Subjects
M. Nakano, Kazunori Uenaka, W. Kielbasa, Y. Matsuyama +2 more
20175 citations Open access
Semantic Scholar
The effect of hepatic or renal impairment on the pharmacokinetics of edivoxetine, a selective norepinephrine transporter reuptake inhibitor
W. Kielbasa, Eshetu Tesfaye, D. Luffer-Atlas, M. Mitchell +1 more
2013European Journal of Clinical Pharmacology4 citations Open access
Semantic Scholar
A D1 receptor positive allosteric modulator (LY3154207) enhances wakefulness in sleep deprived healthy volunteers (P3.6-041)
Kevin Biglan, P. Ardayfio, W. Kielbasa, Kjell A. Svensson
2019Neurology3 citations
Semantic Scholar
Pharmacokinetic and Pharmacodynamic Modeling of LY2951742, a Calcitonin Gene Related Peptide Antibody, in Migraine Patients (P6.091)
W. Kielbasa, Tonya Quinlan, Robert L. Bell, B. Miller +1 more
2016Neurology3 citations
Semantic Scholar
Microdialysis to Assess Free Drug Concentration in Brain
W. Kielbasa, R. Stratford
20153 citations
Semantic Scholar
Relationship of the Calcitonin Gene‐Related Peptide Monoclonal Antibody Galcanezumab Pharmacokinetics and Capsaicin‐Induced Dermal Blood Flow in Healthy Subjects
J. Fiedler-Kelly, E. Raddad, J. Hoon, E. Ludwig +3 more
2021Clinical pharmacology in drug development2 citations Open access
Semantic Scholar
Relationship between pharmacokinetics and hemodynamic effects of inhaled isobutyl nitrite in conscious rats.
W. Kielbasa, H. Fung
2000AAPS PharmSci2 citations
Semantic Scholar
A single ascending dose (SAD) study of a D1 receptor positive allosteric modulator (LY3154207) in healthy volunteers (P4.7-004)
Kjell A. Svensson, P. Ardayfio, W. Kielbasa, Kevin Biglan
2019Neurology1 citations
Semantic Scholar
PKPD Modeling of Brain Receptor Occupancy from Animal to Man for Establishing the Clinical Dose of the NK-1 Antagonist LY686017
C. Falcoz, Wenping Wang, W. Ebling, L. Claret +3 more
20081 citations
Semantic Scholar
P1‐057: A MULTIPLE ASCENDING‐DOSE STUDY OF THE PHARMACOKINETICS AND SAFETY OF LY3154207, A CENTRALLY‐ACTING DOPAMINE D1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR (D1 PAM), IN HEALTHY SUBJECTS
K. Biglan, Kjell A. Svensson, D. Wilbraham, Max C. Tsai +1 more
2019Alzheimer's & Dementia0 citations Open access
Semantic Scholar
Immunogenicity Assessment from Phase 3 Galcanezumab Trials in Patients with Episodic or Chronic Migraine (P1.10-017)
James Martinez, Nada Hindiyeh, Greg Anglin, K. Kalidas +5 more
2019Neurology0 citations
Semantic Scholar
The effect of hepatic or renal impairment on the pharmacokinetics of edivoxetine, a selective norepinephrine transporter reuptake inhibitor
W. Kielbasa, Eshetu Tesfaye, D. Luffer-Atlas, M. Mitchell +1 more
2013European Journal of Clinical Pharmacology0 citations Open access
Semantic Scholar
Exploratory Translational Modeling Approach in Drug Development to Predict Human Brain Pharmacokinetics and Pharmacologically Relevant Clinical Doses
W. Kielbasa, Jr R.E. Stratford, E. Lilly
20120 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

K. Biglan×8
Invite
K. Biglan — researcher profile on SciRah
D. Mergott×6
Invite
D. Mergott — researcher profile on SciRah
S. L. Lowe×5
Invite
S. L. Lowe — researcher profile on SciRah
Emily C. Collins×4
Invite
Emily C. Collins — researcher profile on SciRah

×4

Invite

Tonya Quinlan — researcher profile on SciRah

Kjell A. Svensson×4

Invite

Kjell A. Svensson — researcher profile on SciRah

Invite

K. Phipps — researcher profile on SciRah

Hugh Norman Nuthall×4

Invite

D. Gehlert — researcher profile on SciRah

Invite

J. Tauscher — researcher profile on SciRah

Nicolas Dreyfus×3

Invite

Nicolas Dreyfus — researcher profile on SciRah

Invite

R. Gunn — researcher profile on SciRah